METHOD OF ANTISTRESS MACULAR RETINA PROTECTION IN CATARACT SURGERY IN COMPLICATED DIABETES PATIENTS Russian patent published in 2009 - IPC A61F9/00 A61N1/32 A61K31/711 A61K38/38 A61P27/02 

FIELD: medicine.

SUBSTANCE: invention refers to ophthalmology and can be used for antistress macular retina protection in cataract surgery in diabetes patients before, during and after operation. One day prior to operation the patient is exposed to single 30-minute "ТЭС" therapy session with using an apparatus Transair-01 at bipolar rectangular pulse current of fixed frequency and duration. After the session and the operation day 0.25% Derinate solution is instilled 2 drops per each nostril. It is combined with intravenous droplet introduction of 1.5% Reamberine solution 200 ml. From first postoperative day, 20% Levocarnitine solution is prescribed 3 times a day in dose 1 ml or 1 tablet combined with 0.25% Derinate solution instilled 3 times a day in dose 2 drops per each nostril at the same frequency rate. Combined postoperative Levocarnitine and Derinate therapy lasts from the character of reciprocal morphological macular retina reaction on surgical stress. If macular retina volume gains within the first 3-5 postoperative 10% of average norm, treatment length is 10 days, and 30 days, if 10% are exceeded.

EFFECT: improved antistress macular retina protection by replacing deficiency of plastic protein substrates in photoreceptors.

3 ex, 1 tbl